Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Cited by (1,007)

Items 401–500 of 1,007

1. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays
   Emelissa J. Valcourt, K. Manguiat, Alyssia Robinson, Yi-Chan Lin, K. Abe, S. Mubareka, A. Shigayeva, Zoe Zhong, Roxie C. Girardin, Alan P. Dupuis et al. · 2021 · Microbiology spectrum
2. SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020
   Liza Coyer, Anders C. Boyd, Janke Schinkel, Charles O Agyemang, Henrike Galenkamp, Anitra D.M. Koopman, Tjalling Leenstra, Eric P. Moll van Charante, Bert‐Jan H. van den Born, Anja Lok et al. · 2022 · BMJ Open
3. Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
   Raquel Guiomar, Ana João Santos, Aryse Martins Melo, Inês Costa, Rita Matos, Ana Paula Rodrigues, Irina Kislaya, Anabela Santos Silva, Carla Roque, Carla Nunes et al. · 2022 · Vaccines
4. Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity
   Stefani N. Thomas, Amy B. Karger, Ghaith Altawallbeh, Kathryn M. Nelson, David R. Jacobs, Jed B. Gorlin, Helene Barcelo, Bharat Thyagarajan · 2022 · Scientific Reports
5. The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023
   Chunsheng Cai, Guangdong Field Epidemiology Training Program, Guangzhou City, Guangdong Province, China, Yihong Li, Ting Hu, Rongwei Liang, Kaibin Wang, Congrui Guo, Yan Li, Meng Zhang, Min Kang · 2023 · China CDC Weekly
6. Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study
   Jelena Bešević, Ben Lacey, Howard Callen, Wemimo Omiyale, Megan C. Conroy, Qi Feng, Derrick W. Crook, Nicola Doherty, Daniel V. Ebner, David W. Eyre et al. · 2023 · Journal of Epidemiology & Community Health
7. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice
   Chih-Yun Lai, Albert To, Teri Ann S. Wong, Michael M. Lieberman, David E. Clements, James T. Senda, Aquena H. Ball, Laurent Pessaint, Hanné Andersen, Wakako Furuyama et al. · 2021 · Vaccine X
8. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
   Xiangyang Yao, Wei Yong Liu, Zhiyong Li, Hualong Xiong, Yingying Su, Tingdong Li, Shiyin Zhang, Xuejie Zhang, Zhaofeng Bi, Chen-Xi Deng et al. · 2020 · medRxiv
9. Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine
   Guangli Hu, Xin Luo, Jiamin Liao, Chuangchao Zou, Yihui Huang, Rui Geng, Zhiqing Zhao, Hanqin Shen, Yongchang Cao, Ouyang Peng et al. · 2025 · Veterinary Quarterly
10. Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection
    Jenny A Doust, Katy Bell, Mariska Leeflang, Jacqueline Dinnes, Sarah J. Lord, Susan Mallett, Janneke H. H. M. van de Wijgert, Sverre Sandberg, Khosrow Adeli, Jonathan James Deeks et al. · 2021 · BMJ
11. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
    Bernd Jahrsdörfer, Rüdiger M. Groß, Alina Seidel, Lukas Wettstein, Carolin Ludwig, Tatjana Schwarz, Sixten Körper, Markus Rojewski, Ramin Lotfi, Christoph Weinstock et al. · 2021 · The Journal of Immunology
12. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
    Amit Saxena, Allison Guttmann, Mala Masson, Mimi Kim, Rebecca H. Haberman, Rochelle Castillo, José U. Scher, Kristina Deonaraine, Alexis Engel, Michael H Belmont et al. · 2021 · The Lancet Rheumatology
13. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study
    Ghobad Moradi, Amjad Mohamadi Bolbanabad, Sanaz Ahmadi, Abbas Aghaei, Fares Bahrami, Arshad Veysi, Rasool Nasiri Kalmarzi, Azad Shokri, Ebrahim Ghaderi, Behzad Mohsenpour et al. · 2021 · International Immunopharmacology
14. Prevalence, Persistence, and Factors Associated with SARS-CoV-2 IgG Seropositivity in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital in Northern Italy
    Gitana Scozzari, Cristina S. Costa, Enrica Migliore, Maurizio Coggiola, Giovannino Ciccone, Luigi Savio, Antonio Scarmozzino, Enrico Pira, Paola Cassoni, Claudia Galassi et al. · 2021 · Viruses
15. Public views about COVID-19 ‘Immunity Passports’
    Mark A. Hall, David M. Studdert · 2021 · Journal of Law and the Biosciences
16. SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
    Vimvara Vacharathit, Sirawat Srichatrapimuk, Suwimon Manopwisedjaroen, Suppachok Kirdlarp, Chanya Srisaowakarn, Chavachol Setthaudom, Nanthicha Inrueangsri, Prapaporn Pisitkun, Mongkol Kunakorn, Suradej Hongeng et al. · 2021 · International Journal of Infectious Diseases
17. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays
    Niamh Allen, Melissa Brady, Antonio Isidro Carrión Martín, Lisa M. Domegan, Cathal Walsh, Elaine Houlihan, Colm Kerr, Lorraine Doherty, Joanne King, Martina Doheny et al. · 2021 · Microbiology Spectrum
18. Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence
    Riccardo Sarzani, Francesco Spannella, Federico Giulietti, Chiara Di Pentima, Piero Giordano, Andrea Giacometti · 2021 · Internal and Emergency Medicine
19. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
    Nungruthai Suntronwong, Suvichada Assawakosri, Sitthichai Kanokudom, Ritthideach Yorsaeng, Chompoonut Auphimai, Thanunrat Thongmee, Preeyaporn Vichaiwattana, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon et al. · 2022 · Diagnostics
20. Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
    Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta · 2023 · International Journal of Molecular Sciences
21. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients
    Bertram Flehmig, Michael Schindler, Natalia Ruétalo, Ramona Businger, Manfred Bayer, Angelika Haage, Thomas Kirchner, Karin Klingel, Andrea Normann, Lutz Pridzun et al. · 2020 · Viruses
22. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
    Yaolin Guo, Tianyi Li, Xinyi Xia, Bin Su, Hanping Li, Yingmei Feng, Jingwan Han, Xiaolin Wang, Lei Jia, Zuoyi Bao et al. · 2021 · Frontiers in Immunology
23. Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals
    Liina Tserel, Piia Jõgi, Paul Naaber, Julia Maslovskaja, Annika Häling, Ahto Salumets, Eva Žusinaite, Hiie Soeorg, Freddy Lättekivi, Diana Ingerainen et al. · 2021 · Frontiers in Immunology
24. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
25. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]
    Jayne Doherty, Neil O Morain, Róisín Stack, Parker Girod, Miriam Tosetto, Rosanna Inzitiari, Juliette Sheridan, Garret J. Cullen, Edel McDermott, Maire Buckley et al. · 2022 · Journal of Crohn s and Colitis
26. Paper-based multi-well depletion ELISA
    Dohwan Lee, Norh Asmare, Ali Fatih Sarioglu · 2022 · Lab on a Chip
27. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
    Lisa Seekircher, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, David Bante, Lukas Forer, Sebastian Schönherr, Zoltán Bánki et al. · 2023 · The Lancet Microbe
28. Selecting COVID ‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV ‐2 antibody assay
    Erin Meyer, Graham Simmons, Eduard Grebe, Michael Sel Gannett, Sergej Franz, Orsolya Darst, Clara Di Germanio, Mars Stone, Paul Contestable, Alicia Bellido Prichard et al. · 2021 · Transfusion
29. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
    Seyede Atefe Hosseini, Fatemeh Zahedipour, Hamed Mirzaei, Reza Kazemi Oskuee · 2021 · International Immunopharmacology
30. Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
    Ghina R. Mumtaz, Fadi El‐Jardali, Mathilda Jabbour, Aya Harb, Laith Jamal Abu-Raddad, Monia Makhoul · 2021 · Vaccines
31. Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variants
    Jamie A. Cohen, Robyn M. Stuart, Katherine Rosenfeld, Hil M. Lyons, Michael T. White, Cliff C. Kerr, Daniel J. Klein, Michael Famulare · 2021 · medRxiv
32. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
    Isaac Kyei-Barffour, Samuel Akwetey Addo, E. Aninagyei, George Ghartey-Kwansah, D. O. Acheampong · 2021 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
33. Cigarette Smoke Exposure, Pediatric Lung Disease, and COVID-19
    Marta Schiliro, Elizabeth R. Vogel, Lucia Paolini, Christina M. Pabelick · 2021 · Frontiers in Physiology
34. Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
    Aisha D. Fakhroo, Hebah A. Al-Khatib, Asmaa A. Al Thani, Hadi Mohamad Yassine · 2021 · Vaccines
35. The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors
    Mengqi Xiang, Xiaoming Wu, Haijiao Jing, Langjiao Liu, Chunxu Wang, Yufeng Wang, Valerie Anne Novakovic, Jialan Shi · 2022 · Frontiers in Immunology
36. Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
    Fatima Amanat, Jordan J. Clark, Juan Manuel Carreño, Shirin Strohmeier, Temima Yellin, Philip S. Meade, Disha Bhavsar, Hiromi Muramatsu, Weina Sun, Lynda Coughlan et al. · 2023 · Journal of Virology
37. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
    Grace Kenny, Sophie R O’Reilly, Neil E. Wrigley Kelly, Riya Negi, Colette Marie Gaillard, Dana Alalwan, Gurvin Saini, Tamara Alrawahneh, Nathan Francois, Matthew Angeliadis et al. · 2023 · Nature Communications
38. India’s pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis
    Sandip Mandal, Nimalan Arinaminpathy, Balram Bhargava, Samiran Panda · 2021 · BMJ Open
39. Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers
    Felicia Trofin, Eduard Vasile Năstase, Luminița Smaranda Iancu, Daniela Constantinescu, Corina Maria Cianga, Cătălina Luncă, Ramona Gabriela Ursu, Petru Cianga, Olivia Dorneanu · 2022 · Pathogens
40. Immune response induced by novel coronavirus infection
    Ying Sun, Yawen Zou, Haiyu Wang, Guang-Ying Cui, Zujiang Yu, Zhi-Gang Ren · 2022 · Frontiers in Cellular and Infection Microbiology
41. A simple protein-based surrogate neutralization assay for SARS-CoV-2
    Kento T. Abe, Zhijie Li, Reuben Samson, Payman Samavarchi-Tehrani, Emelissa J. Valcourt, Heidi Wood, Patrick Budylowski, Alan P. Dupuis, Roxie C. Girardin, Bhavisha Rathod et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
42. Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells
    P. Mishra, N. Bruiners, Rahul Ukey, Pratik Datta, A. Onyuka, D. Handler, Sabiha M. Hussain, W. Honnen, Sukhwinder Singh, V. Guerrini et al. · 2021 · medRxiv
43. SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
    Eric D. Laing, Nusrat J Epsi, Stephanie A Richard, Emily C Samuels, Wei Wang, Russell A. Vassell, Daniel F. Ewing, Rachel Herrup, Spencer L. Sterling, David A Lindholm et al. · 2021 · medRxiv
44. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
    Thomas W. Barnes, Johannes Schulte-Pelkum, Laura Steller, Daniel Filchtinski, Robin Jenness, Michelle R. Williams, Christina Kober, Sandro Manni, Thomas Hauser, Aaron Hahn et al. · 2021 · Clinical Immunology
45. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
    Kevin W. Ng, Nikhil Faulkner, Antoni G. Wrobel, Steve J. Gamblin, George Kassiotis · 2021 · Seminars in Immunology
46. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
    Indrė Kučinskaitė-Kodzė, Martynas Simanavičius, Aistis Šimaitis, Aurelija Žvirblienė · 2021 · Viruses
47. Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model
    Kuan‐Ting Liu, Yu‐Nong Gong, Chung‐Guei Huang, Peng-Nien Huang, Kar-Yee Yu, Hou-Chen Lee, Sun-Che Lee, Huan-Jung Chiang, Yu-An Kung, Yueh‐Te Lin et al. · 2022 · mSphere
48. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
    Robert H. Bortz, Catalina Florez, Ethan Laudermilch, Ariel S. Wirchnianski, Gorka Lasso, Ryan J. Malonis, George Ivanov Georgiev, Olivia Vergnolle, Natalia G. Herrera, Nicholas C. Morano et al. · 2021 · mSphere
49. Vaccine against COVID-19
    Juan Jose Picazo · 2021 · Revista Española de Quimioterapia
50. Toward Smart Diagnostics in a Pandemic Scenario: COVID-19
    Mohammad Hosseinifard, Tina Naghdi, Eden Morales‐Narváez, Hamed Golmohammadi · 2021 · Frontiers in Bioengineering and Biotechnology
51. Reinfection in COVID-19: A scoping review
    Lancelot Pinto, Viral Nanda, Ayesha Sunavala, Camilla Rodriques · 2021 · Medical Journal Armed Forces India
52. High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay
    Markus H. Kainulainen, Éric Bergeron, Payel Chatterjee, Asheley Poole Chapman, Joo Sang Lee, Asiya Seema Chida, Xiaoling Tang, Rebekah E. Wharton, Kristina B. Mercer, Marla Petway et al. · 2021 · Scientific Reports
53. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
    Shai Efrati, Merav Catalogna, Ramzia Abu Hamad, Amir Hadanny, Adina Bar‐Chaim, Patricia Benveniste‐Levkovitz, Osnat Levtzion‐Korach · 2021 · Scientific Reports
54. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
    Stefan Glöckner, Franziska Hornung, Michael Baier, Sebastian Weis, Mathias Wilhelm Pletz, Stefanie Deinhardt‐Emmer, Bettina Löffler, the CoNAN Study Group · 2021 · Viruses
55. Antibody Dynamics and Durability in Coronavirus Disease-19
    Adam Zuiani, Duane R. Wesemann · 2021 · Clinics in Laboratory Medicine
56. Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication
    Daseuli Yu, Hee-Jeong Han, Jeonghye Yu, Jihye Kim, Gun‐Hee Lee, Ju-Hee Yang, Byeong-Min Song, Dongseob Tark, Byeong‐Sun Choi, Sangmin Kang et al. · 2023 · Molecular Therapy
57. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response
    Seniha Başaran, Serap Şimşek Yavuz, Sevim Meşe, Atahan Çağatay, Alpay Medetalibeyoğlu, Oral Öncül, Halit Özsüt, Ali Ağaçfidan, Ahmet Gül, Haluk Eraksoy · 2021 · International Journal of Infectious Diseases
58. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors
    Atsushi Goto, Hirofumi Go, Kei Miyakawa, Yutaro Yamaoka, Norihisa Ohtake, Sousuke Kubo, Sundararaj Stanleyraj Jeremiah, Takahiro Mihara, Kotaro Senuki, Tomoyuki Miyazaki et al. · 2021 · Frontiers in Microbiology
59. Evaluation of spike protein antigens for SARS-CoV-2 serology
    Suraj Jagtap, K Ratnasri, Priyanka Valloly, Rakhi Sharma, Satyaghosh Maurya, Anushree Gaigore, Chitra Ardhya, Dayananda S Biligi, Bapu Koundinya Desiraju, Uma Chandra Mouli Natchu et al. · 2021 · Journal of Virological Methods
60. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection
    Gemma D. Banham, Alexandra Godlee, Sian Elizabeth Faustini, Adam F. Cunningham, Alex G Richter, Lorraine Harper, on behalf of the COVID-HD Birmingham Study Group · 2021 · Journal of the American Society of Nephrology
61. Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies
    Magdalena M. Zak, Aryeh Stock, D. Stadlbauer, Wei Zhang, K. Cummings, William Marsiglia, Arsen Zargarov, Fatima Amanat, M. Tamayo, C. Cordon-Cardo et al. · 2021 · Heliyon
62. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort
    Hoa Thi My Vo, Alvino Maestri, Heidi Auerswald, Sopheak Sorn, Sokchea Lay, Heng Seng, Sotheary Sann, Nisa Ya, Polidy Pean, Philippe Dussart et al. · 2022 · Frontiers in Immunology
63. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases
    Keren Masha Rabinowitz, Michal Navon, Hadar Edelman-Klapper, Eran Zittan, Ariella Bar‐Gil Shitrit, Idan Goren, Irit Avni‐Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran et al. · 2022 · Vaccines
64. A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
    Megan A. O’Connor, David W. Hawman, Kimberly D. Meade-White, Shanna S. Leventhal, Wenjun Song, Samantha Randall, Jacob F. Archer, Thomas B. Lewis, Brieann Brown, Megan Fredericks et al. · 2023 · PLoS Pathogens
65. Longitudinal dynamics of antibody responses in recovered COVID-19 patients
    Meng‐Li Cheng, Huiying Liu, Hui John Zhao, Guoqing Wang, Chao Hui ZHOU, Jing Zheng, Xiaofeng Li, Fan Li, Changqing Bai, Cheng‐Feng Qin · 2021 · Signal Transduction and Targeted Therapy
66. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
    Lee, Wen Shi, Selva, Kevin John, Davis, Samantha K., Wines, Bruce D., Reynaldi, Arnold, Esterbauer, Robyn, Kelly, Hannah G., Haycroft, Ebene R., Tan, Hyon-Xhi, Juno, Jennifer A. et al. · 2020
67. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy
    Devarasetti, Phani Kumar, Rajasekhar, Liza, Baisya, Ritasman, Sreejitha, K. S., Vardhan, Yerram Keerthi · 2021 · Immunologic Research
68. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants
    Mengxiao Luo, Runhong Zhou, Bingjie Tang, Hang Liu, Bo‐Hao Chen, Na Liu, Yufei Mo, Pengfei Zhang, Ye Lim Lee, Jonathan Daniel Ip et al. · 2024 · EBioMedicine
69. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
    Roxie C. Girardin, Alan P. Dupuis, Anne F. Payne, Timothy J Sullivan, Donna Strauss, Monica M. Parker, Kathleen A. McDonough · 2020 · The Journal of Infectious Diseases
70. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients
    Christelle Vauloup‐Fellous, Sarah Maylin, Claire Périllaud-Dubois, Ségolène Brichler, Chakib Alloui, Emmanuel Gordien, Marie‐Anne Rameix‐Welti, Elyanne Gault, F. Moreau, Slim Fourati et al. · 2021 · European Journal of Clinical Microbiology & Infectious Diseases
71. A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals
    Yvelise Barrios, Andrés Franco, Inmaculada Sánchez‐Machín, Paloma Poza Guedes, Ruperto González‐Pérez, Victor M. Matheu · 2021 · Clinical Immunology
72. Analysis of long‐term antibody response in COVID‐19 patients by symptoms grade, gender, age, BMI, and medication
    Tuba Özgöçer, Seyda Nur Daglı, Mehmet Reşat Ceylan, Faruk Dişli, Cihat Uçar, Sedat Yıldız · 2021 · Journal of Medical Virology
73. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2
    Ingrid Siciliano Horbach, Adriana de Souza Azevedo, Waleska Dias Schwarcz, Nathalia dos Santos Alves, Brenda de Moura Dias, Bruno Pimenta Setatino, Luma da Cruz Moura, Ariane Faria de Souza, Caio Bidueira Denani, Stephanie Almeida da Silva et al. · 2024 · Diseases
74. SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses
    Leire de Campos-Mata, Sonia Tejedor Vaquero, Roser Tachó-Piñot, Janet Piñero, E. Grasset, I. Arrieta Aldea, N. Rodrigo Melero, C. Carolis, J. Horcajada, A. Cerutti et al. · 2021 · medRxiv
75. Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave
    Nausicaa Berselli, Tommaso Filippini, Stefania Paduano, Marcella Malavolti, Alberto Modenese, Fabriziomaria Gobba, Paola Borella, Isabella Marchesi, Roberto Vivoli, Paola Perlini et al. · 2021 · International Journal of Occupational Medicine and Environmental Health
76. Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection
    Victor A. Manuylov, O. Burgasova, Olga V. Borisova, Сметанина Светлана Васильевна, Daria V. Vasina, Igor V. Grigoriev, A. M. Kudryashova, Maria A. Semashko, Черепович Богдан Сергеевич, Харченко Ольга Сергеевна et al. · 2022 · Viruses
77. Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients
    Julien Favresse, Marc Elsen, Christine Eucher, Kim Laffineur, Sandrine Van Eeckhoudt, Jean‐Baptiste Nicolas, Constant Gillot, Jean-Michel Dogné, Jonathan Douxfils · 2020 · Clinical Chemistry and Laboratory Medicine (CCLM)
78. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
    Fatima Amanat, Shirin Strohmeier, Wen-Hsin Lee, Sandhya Bangaru, Andrew B. Ward, Lynda Coughlan, Florian Krammer · 2021 · mBio
79. Immune Responses against SARS-CoV-2—Questions and Experiences
    Harald Mangge, Markus Kneihsl, Wolfgang Johann Schnedl, Gerald Sendlhofer, Francesco Curcio, Rossana Domenis · 2021 · Biomedicines
80. SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract
    Frederick Hansen, Kimberly D. Meade-White, Chad S. Clancy, Rebecca Rosenke, Atsushi Okumura, David W. Hawman, Friederike Feldmann, Benjamin Kaza, Michael A. Jarvis, Kyle Rosenke et al. · 2022 · Cell Reports
81. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020
    Shuting Zhang, Peijun Ma, Marek Orzechowski, Allison Lemmer, Kara M. Rzasa, Josephine Bagnall, Sulyman Barkho, Michael Chen, Lorrie L. He, Raymond Neitupski et al. · 2023 · mBio
82. Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology
    Mohamed M. Shamseldin, Ashley Zani, Adam Kenney, John Parker Evans, Cong Zeng, Kaitlin A. Read, Kyle Caution, Jesse M. Hall, Jessica Marlene Brown, Gilian Gunsch et al. · 2023 · The Journal of Immunology
83. The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera
    Gagandeep Singh, Anass Abbad, Giulio Kleiner, Komal Srivastava, Charles Gleason, PARIS Study Group, Juan Manuel Carreño, Viviana R. Simon, Florian Krammer, Dalles Andre et al. · 2023 · mBio
84. SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
    Alba Escalera, Amaya Rojo-Fernandez, Alexander Rombauts, Gabriela Abelenda-Alonso, Jordi Carratalà, Adolfo García‐Sastre, Teresa Aydillo · 2024 · iScience
85. A framework for monitoring population immunity to SARS-CoV-2
    Benjamin Alan Lopman, Kayoko Shioda, Quan Nguyen, Stephen J. Beckett, Aaron Julius Siegler, Patrick Sean Sullivan, Joshua S. Weitz · 2021 · Annals of Epidemiology
86. Analytical and clinical performance of cPass neutralizing antibodies assay
    Joanna Jung, Deepthi Rajapakshe, Christopher Julien, Sridevi Devaraj · 2021 · Clinical Biochemistry
87. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers
    Kasper Karmark Iversen, Jonas Henrik Kristensen, Rasmus Bo Hasselbalch, Mia Marie Pries‐Heje, Pernille Brok Nielsen, Andreas Dehlbæk Knudsen, Kamille Fogh, Jakob Boesgaard Norsk, Ove Andersen, Thea Kølsen Fischer et al. · 2021 · Clinical Microbiology and Infection
88. Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020
    Zengmiao Wang, Jason D. Whittington, Hsiang‐Yu Yuan, Hui Miao, Huaiyu Tian, Nils Chr. Stenseth · 2021 · Biosafety and Health
89. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2
    Gyoung Nyoun Kim, Jung-ah Choi, Kunyu Wu, Nasrin Saeedian, Eunji Yang, Hayan Park, Sun‐Je Woo, Gippeum Lim, Seong-Gyu Kim, Su-Kyeong Eo et al. · 2021 · PLoS Pathogens
90. Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests
    Gabriel N. Maine, Subhashree Mallika Krishnan, Kelly Walewski, Jillian Trueman, Elizabeth Sykes, Qian Sun · 2022 · Journal of Immunological Methods
91. Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    Jennifer M. Dan, Ricardo da Silva Antunes, Alba Grifoni, Daniela Weiskopf, Shane Crotty, Alessandro Sette · 2022 · Clinical Infectious Diseases
92. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
    Clara Udaondo, Carmen Cámara, Laura Miguel‐Berenguel, Rosa Alcobendas, Celia Muñoz-Gómez, Claudia Millán Longo, Blanca Díaz – Delgado, Iker Falces‐Romero, Mariana Díaz Almirón, Jordi Ochando et al. · 2022 · Pediatric Rheumatology
93. Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
    Sophie C. Frölke, Pim Bouwmans, A. Lianne Messchendorp, Suzanne E. Geerlings, Marc H. Hemmelder, Ron T. Gansevoort, Luuk B. Hilbrands, Marlies E. J. Reinders, Jan‐Stephan Sanders, Fréderike J. Bemelman et al. · 2022 · Transplantation Direct
94. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
    Holly A. Fryer, Gemma E. Hartley, Emily S.J. Edwards, Robyn E. O’Hehir, Menno C. van Zelm · 2022 · Biochemical Society Transactions
95. MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection
    Janie Rae Byrum, Eric Waltari, Owen Janson, Syuan-Ming Guo, Jenny Folkesson, Bryant B. Chhun, Joanna Vinden, Ivan E. Ivanov, Marcus L. Forst, Hongquan Li et al. · 2023 · Pathogens
96. A new approach to the dynamic modeling of an infectious disease
    B. Shayak, Mohit Sharma · 2021 · Mathematical Modelling of Natural Phenomena
97. Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
    L. Muir, Aneesa Jaffer, C. Rees-Spear, Vignesh Gopalan, F. Chang, R. Fernando, Gintare Vaitkute, C. Roustan, Annachiara Rosa, Christopher Earl et al. · 2021 · Kidney International Reports
98. Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
    Ruth A Purcell, Robert M. Theisen, Kelly B. Arnold, Amy W. Chung, Kevin John Selva · 2023 · Frontiers in Immunology
99. Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
    Laurence S. C. Lok, Shuvam Sarkar, Calista Chi In Lam, C. Law, Sin Teng Chau, Chun Yip Thomas Leung, Wai Hin Cheang, Ting Li, Olivia Monteiro, Daniel Tomas Baptista‐Hon · 2024 · MedComm – Future Medicine
100. Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
     Anja Garritsen, Anja Scholzen, Daan W. A. van den Nieuwenhof, Anke P. F. Smits, E. Suzan Datema, Luc S. van Galen, Milou Kouwijzer · 2021 · Scandinavian Journal of Infectious Diseases